Avid Bioservices Inc (CDMO)

[freethemice]

All this talk about first and second-line NSCLC differences gives me thought about what is going on with
the second-line trial. If you remember this post of mine
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73652352
I still think there could be a synergy with docetaxel that results in these incredible interim MOS numbers.
That may be possible because of feedbacks in the tumor microenvironment. During the time of treatment
(6 3-week cycles) the combination of docetaxel + bavituximab might reverse the immunosuppressive tumor
microenvironment and allow the adaptive immune response to kick in. Once the treatment cycles are done
patients who did develop such a response now have at least a partial immunity to the recurrence of the disease.
That could explain the long survival times. So it could be particular to the docetaxel + bavi combo, but the same
could happen with other chemo combinations. What I am saying is that what is going on is more than
just the increased exposure of PS that does occur with radiation and chemo drugs. Without the synergy
maybe you get 50% increase in MOS over control, with the synergy you get 100+%. So it wouldn't surprise
me if some of the trials with bavi work much better than others, but it wouldn't necessarily depend on the
indication, but on the combo used. There is still a lot we don't understand about all of this, it is cutting edge stuff.
Just trying to think out of the box. It is a beautiful day outside so I am out of here!